CG MED EQUIP.
838810
BEOKA
870199
Shenzhen Bromake New Material
301387
4
Zhejiang Hongchang Electrical Technology
301008
5
Wuhan Lincontrol Automotive Electronics Co., Ltd.
688667
CN Stock MarketDetailed Quotes
688488 Jiangsu Aidea Pharmaceutical
- 12.08
- +0.72+6.34%
Market Closed Apr 30 15:00 CST
5.08BMarket Cap-45.41P/E (TTM)
12.17High11.30Low219.84KlotVolume11.48Open11.36Pre Close258.90MTurnover5.23%Turnover RatioLossP/E (Static)420.78MShares17.3352wk High5.10P/B5.08BFloat Cap6.5852wk Low13.63Limit Up420.78MShs Float45.21Historical High9.09Limit Down7.66%Amplitude6.58Historical Low--Dividend TTM11.78Avg Price80.68KlotAsk--Div YieldTTM100Lot Size130.47KlotBid
Jiangsu Aidea Pharmaceutical News
Jiangsu Aidea Pharmaceutical Co., Ltd.'s (SHSE:688488) Market Cap Rose CN¥682m Last Week; Individual Investors Who Hold 31% Profited and so Did Insiders
Eddy Pharmaceuticals: Eddy Pharmaceuticals 2024 Annual Report Summary
Eddy Pharmaceuticals: Eddy Pharmaceuticals Report for the First Quarter of 2025
Eddy Pharmaceuticals: Eddy Pharmaceuticals 2024 Annual Report
Eddy Pharmaceuticals 2024 Annual Report
Eddy Pharmaceuticals 2024 Annual Report Summary
Eddy Pharmaceuticals 2025 First Quarter Report
Jiangsu Aidea Pharmaceutical (688488.SH): project cooperation development framework contract terminated with Pharma Block Sciences.
On April 8th, Gelonghui reported that Jiangsu Aidea Pharmaceutical (688488.SH) announced that the company and its wholly-owned subsidiary Nanjing Aidea Pharmaceutical Technology Co., Ltd. signed the "Project Cooperation Development Framework Contract" (referred to as the "original framework contract") with Nanjing Pharma Block Sciences Co., Ltd. (hereinafter referred to as "Pharma Block Sciences" or "Party B") in August 2022 after friendly consultations. Both parties intend to jointly develop new drugs in the field of innovative targets and innovative compounds for 3CL protease inhibitors against the novel coronavirus pneumonia. Due to significant changes in the objective environment and market outlook of this project, both parties have reached a consensus through friendly negotiations to terminate the original framework contract and its annex in advance.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
The "wind" has reached the pharmaceutical stocks, and the Sector is experiencing a surge in limit-up prices! What are the Bullish catalysts?
Catalysts from news, warming performance, and the advantages of valuation may become the main factors boosting the rise of pharmaceutical stocks.
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Jiangsu Aidea Pharmaceutical Gets Clinical Trial Approval for AD108 Injection
Jiangsu Aidea Pharmaceutical (688488.SH): AD108 injection has received the drug clinical trial approval notice.
On March 13, 2023, Gelonghui reported that Jiangsu Aidea Pharmaceutical (688488.SH) announced that the company and its holding subsidiary, Nanjing Nanda Pharmaceutical Co., Ltd., received the "Notice of Drug Clinical Trial Approval" (referred to as the "Notice") issued by the National Medical Products Administration on March 12, 2025, approving the company to conduct Phase I clinical trials of the 2.2 class modified new drug AD108 injection. AD108 injection is a modified new drug (Chemical Drug class 2.2), with the active ingredient being human prorenin enzyme, specifically tissue type kallikrein-1 (KLK-1), which is a serine protease secreted by the kidneys.
Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) Looks Just Right With A 28% Price Jump
Eddy Pharmaceuticals 2024 Annual Results Express Announcement
Jiangsu Aidea Pharmaceutical (688488.SH): Net loss of 0.13 billion yuan for the year 2024.
Gelonghui February 27丨Jiangsu Aidea Pharmaceutical (688488.SH) announced the performance report for 2024. During the reporting period, the company's total operating revenue was 419.265 million yuan, an increase of 1.92% compared to the same period last year; the operating profit was -151.8265 million yuan, which is a decrease of 64.94% compared to the same period last year; the total profit was -153.0564 million yuan, which represents a decrease of 66.21% compared to the same period last year; the net income attributable to the owners of the parent company was -129.9185 million yuan, a decrease of 70.79% compared to the same period last year; the net income attributable to the owners of the parent company after deductions.
Eddy Pharmaceuticals 2024 Annual Results Forecast
Jiangsu Aidea Pharmaceutical (688488.SH): Elected Fu Heling as Director.
Gelonghui, January 3rd丨Jiangsu Aidea Pharmaceutical (688488.SH) announced that on January 3, 2025, the company will hold the first meeting of the third Board of Directors, where all directors unanimously agreed to elect Mr. Fu Helian as the chairman of the third Board of Directors.
Jiangsu Aidea Pharmaceutical (688488.SH): New core technical personnel identified as Qin Hong, Li Qide, and Sun Tie.
Jiangsu Aidea Pharmaceutical (688488.SH) issued a notice that the company's senior management and core technical personnel Hong ...
Insiders With Their Considerable Ownership Were the Key Benefactors as Jiangsu Aidea Pharmaceutical Co., Ltd. (SHSE:688488) Touches CN¥4.1b Market Cap